Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GK01 in Advanced Solid Tumors
NCT07414316Phase 1Recruiting
- Sponsor
- Beijing Geek Gene Technology
- Start
- Feb 2026
- Primary completion
- Feb 2027
- Modality
- Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of GK01 in solid tumor (advanced stage), lung cancer and Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Beijing Geek Gene Technology. Primary endpoint: Safety and Tolerability at 2 years. Started Feb 2026; status: recruiting.
02
Drugs
GK01
03
Conditions
solid tumor (advanced stage)lung cancerEsophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07414316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07414316.